Reconciling Investigator and Sponsor Views in Causality Assessments

Introduction: Why Reconciliation Is Critical

In clinical trials, both investigators and sponsors are required to assess whether an adverse event (AE) is related to the investigational product (IP). Investigators provide frontline, patient-level judgments, while sponsors apply a global perspective based on aggregate data and pharmacological knowledge. These dual perspectives are essential, but they often result in discrepancies. Regulators such as the FDA, EMA, and MHRA expect sponsors to reconcile these differences transparently and document them consistently in case report forms (CRFs), safety databases, and regulatory submissions.

Failure to reconcile causality judgments can lead to misreporting of SUSARs, inconsistencies in DSURs or PSURs, and regulatory inspection findings. Reconciliation is therefore not only a scientific responsibility but also a regulatory compliance requirement. This article provides a structured guide to reconciling investigator and sponsor views on causality, supported by regulatory guidance, case studies, challenges, and best practices.

Investigator’s Perspective on Causality

Investigators assess causality based on their direct clinical interaction with participants. Their considerations include:

• Temporal relationship: Did the AE occur shortly after drug administration?
• Clinical plausibility: Does the AE fit the pharmacology of the IP?
• Alternative explanations: Are concomitant medications or disease progression more likely causes?
• Patient-specific context: Does the individual’s medical history provide clues?

For example, in a blinded oncology study, an investigator may classify febrile neutropenia as “Possibly related” to chemotherapy, reflecting patient-level judgment without access to global safety data.

Sponsor’s Perspective on Causality

Sponsors, typically through pharmacovigilance and safety physicians, reassess causality with a broader lens. They consider:

• Aggregate patterns: Frequency of the AE across multiple patients and sites.
• Mechanistic evidence: Preclinical and class-effect knowledge.
• Global literature: Published evidence of drug-related risks.
• Regulatory standards: Requirements for expedited reporting and labeling.

For example, if multiple sites report hepatotoxicity, the sponsor may classify the events as “Probably related” even when some investigators recorded them as “Unlikely.” This ensures that the regulatory submissions capture potential safety signals.

Case Studies of Causality Reconciliation

Case Study 1 – Vaccine Trial Hepatotoxicity: Investigators classified liver enzyme elevations as “Not related,” citing underlying hepatitis. Sponsor pharmacovigilance review noted clustering across vaccinated participants and reclassified the events as “Possibly related.” Regulators emphasized the sponsor’s responsibility to document both views but supported the sponsor’s cautious approach.

Case Study 2 – Oncology Immunotherapy Trial: Immune-mediated colitis was marked as “Unlikely related” by several investigators. Sponsor review identified a class-effect signal, leading to reclassification as “Probably related.” This reassessment was crucial for expedited reporting and updated investigator training.

Case Study 3 – Cardiovascular Device Trial: Chest pain events were inconsistently graded across sites. Sponsor reconciliation harmonized assessments, ensuring uniform reporting and reducing regulatory queries.

Regulatory Expectations for Reconciling Views

Authorities emphasize the importance of transparent reconciliation:

• FDA: Requires inclusion of both investigator and sponsor causality in IND safety reports and CRFs.
• EMA: Mandates dual reporting of causality in SUSAR submissions to EudraVigilance.
• MHRA: Inspects reconciliation processes, citing sponsors who fail to explain differences in causality attribution.
• ICH E2A: Recognizes causality as requiring both site-level and sponsor-level perspectives for robust pharmacovigilance.

Inspection findings often highlight that differences were not adequately explained or reconciled in safety databases, reinforcing the need for structured processes and clear SOPs.

Challenges in Reconciling Causality Assessments

Reconciling views is complex due to:

• Subjectivity: Investigators may downplay causality to avoid trial disruption, while sponsors may over-attribute to safeguard compliance.
• Data inconsistencies: Misalignment between CRFs, SAE narratives, and pharmacovigilance databases.
• Resource constraints: High AE volumes in global trials complicate systematic reconciliation.
• Communication barriers: Sponsors may fail to explain rationale for reclassification back to investigators, creating mistrust.

These challenges require structured workflows, training, and transparency to ensure reconciliation supports both compliance and collaboration.

Best Practices for Effective Causality Reconciliation

To achieve consistent causality alignment, sponsors should adopt best practices:

• Maintain both investigator and sponsor causality in safety databases with timestamped documentation.
• Develop SOPs requiring justification for any sponsor reclassification.
• Use reconciliation reports to track unresolved discrepancies across systems.
• Conduct regular safety review meetings with investigators to discuss disagreements and provide feedback.
• Implement independent adjudication committees for contentious causality cases.

For example, in a Phase III global oncology program, sponsors introduced monthly reconciliation dashboards comparing investigator vs sponsor causality judgments. Discrepancies were flagged, reviewed, and resolved collaboratively, reducing inspection findings by 30%.

Key Takeaways

Reconciling investigator and sponsor causality views is essential for regulatory compliance, patient safety, and scientific integrity. To meet regulatory expectations, sponsors must:

• Document and maintain both perspectives in databases and submissions.
• Justify sponsor reclassifications with evidence from aggregate data.
• Develop SOPs and workflows for systematic reconciliation.
• Engage investigators in transparent communication to ensure alignment.

By adopting these practices, sponsors can avoid regulatory citations, enhance pharmacovigilance accuracy, and strengthen the reliability of clinical trial safety data worldwide.